525 related articles for article (PubMed ID: 29357870)
1. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
2. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
3. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
4. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Milligan R; Daher A; Graves PM
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012656. PubMed ID: 31274189
[TBL] [Abstract][Full Text] [Related]
5. [Role of primaquine in malaria control and elimination in French-speaking Africa].
Briolant S; Pradines B; Basco LK
Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
[TBL] [Abstract][Full Text] [Related]
7. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
8. Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
Nain M; Gill J; Mohan M; Sharma A
Am J Trop Med Hyg; 2023 Mar; 108(3):470-476. PubMed ID: 36746659
[TBL] [Abstract][Full Text] [Related]
9. G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
Satyagraha AW; Sadhewa A; Baramuli V; Elvira R; Ridenour C; Elyazar I; Noviyanti R; Coutrier FN; Harahap AR; Baird JK
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003602. PubMed ID: 25746733
[TBL] [Abstract][Full Text] [Related]
10. Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K; Saravu K
Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
[TBL] [Abstract][Full Text] [Related]
11. G6PD deficiency: global distribution, genetic variants and primaquine therapy.
Howes RE; Battle KE; Satyagraha AW; Baird JK; Hay SI
Adv Parasitol; 2013; 81():133-201. PubMed ID: 23384623
[TBL] [Abstract][Full Text] [Related]
12. G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
Dombrowski JG; Souza RM; Curry J; Hinton L; Silva NRM; Grignard L; Gonçalves LA; Gomes AR; Epiphanio S; Drakeley C; Huggett J; Clark TG; Campino S; Marinho CRF
Malar J; 2017 Jun; 16(1):253. PubMed ID: 28619120
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
14. Primaquine treatment for Plasmodium vivax--an essential tool for malaria control and elimination in Papua New Guinea.
Betuela I; Robinson LJ; Hetzel MW; Laman M; Siba PM; Bassat Q; Mueller I
P N G Med J; 2014; 57(1-4):68-74. PubMed ID: 26930890
[TBL] [Abstract][Full Text] [Related]
15. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
16. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
17. Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
Nain M; Mohan M; Sharma A
Am J Trop Med Hyg; 2022 Jan; 106(3):764-767. PubMed ID: 35008050
[TBL] [Abstract][Full Text] [Related]
18. Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency.
Baird JK
BMC Med; 2015 Dec; 13():296. PubMed ID: 26652887
[TBL] [Abstract][Full Text] [Related]
19. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
[No Abstract] [Full Text] [Related]
20. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
